Trial
NCT04271475
A Study to Evaluate Efficacy and Safety of Macitentan 75 mg in Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Actelion
Collaborators
—
Condition
Chronic Thromboembolic Pulmonary Hypertension
Intervention
Macitentan
Why stopped
The Sponsor decided to stop the study for futility based on a recommendation by the IDMC following a pre-planned interim analysis
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-06-27